Analysts’ Weekly Ratings Updates for West Pharmaceutical Services (WST)

West Pharmaceutical Services (NYSE: WST) recently received a number of ratings updates from brokerages and research firms:

• 7/15/2026 – West Pharmaceutical Services had its “buy” rating reaffirmed by TD Cowen.
• 7/13/2026 – West Pharmaceutical Services is now covered by BNP Paribas Exane. They set an “outperform” rating and a $447.00 price target on the stock.
• 7/9/2026 – West Pharmaceutical Services had its price target raised by Morgan Stanley from $325.00 to $365.00. They now have an “equal weight” rating on the stock.
• 7/6/2026 – West Pharmaceutical Services had its “outperform” rating reaffirmed by Evercore Inc. They now have a $410.00 price target on the stock.
• 7/2/2026 – West Pharmaceutical Services had its price target raised by KeyCorp from $350.00 to $390.00. They now have an “overweight” rating on the stock.
• 6/9/2026 – West Pharmaceutical Services was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $400.00 price target on the stock, up from $310.00.
• 6/2/2026 – West Pharmaceutical Services had its “overweight” rating reaffirmed by Stephens. They now have a $360.00 price target on the stock.
• 6/1/2026 – West Pharmaceutical Services is now covered by Wolfe Research. They set an “outperform” rating and a $375.00 price target on the stock.
• 6/1/2026 – West Pharmaceutical Services was upgraded by Wolfe Research to “outperform”. They now have a $375.00 price target on the stock.
• 5/29/2026 – West Pharmaceutical Services had its price target raised by Morgan Stanley from $315.00 to $325.00. They now have an “equal weight” rating on the stock.

Insider Buying and Selling

In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Chad Winters sold 896 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by insiders.

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.